Avalo Therapeutics, Inc.
Company Stats
- Market Cap
- $822.1M
- as of Sep 30, 2026
- Shares Outstanding
- 53.6M
- Free Float
- 91.0%
Income Statement
- Revenue
- $59,000
- Operating Income
- -$72.9M
- Net Income
- -$78.3M
- EBITDA
- -$72.6M
- Revenue Growth, 3Y
- -85.2%
Balance Sheet
- Cash & Equivalents
- $15.9M
Returns & Capital
- SBC, 3Y Avg
- $7.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $59,000 | — | — |
| FY2024 | $441,000 | — | — |
| FY2023 | $1.9M | -$30.7M | -1594.6% |
| FY2022 | $18.1M | -$26.8M | -148.7% |
| FY2021 | $5.4M | -$71.0M | -1315.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 31, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Passive Ownership Shifts in Index Holdings